ALE.P03 / Alentis Therap - LARVOL DELTA

Novo Holdings co-leads $181.4 million Series D financing in Alentis Therapeutics to advance groundbreaking antibody-drug conjugates (ADCs) for solid tumours (PRNewswire) - "This financing will enable Alentis to begin Phase 1/2 trials for two first-in-class ADCs: ALE.P02, which targets advanced or metastatic CLDN1+ squamous solid tumours with a tubulin inhibitor payload, and ALE.P03, which targets CLDN1+ tumours with a distinct topoisomerase I inhibitor payload. FDA clearance is already obtained for ALE.P02, with clinical trials expected to commence in Q1 2025. For ALE.P03, a first-in-human trial in patients with CLDN1+ tumours is subsequently planned to start in 2025."

Financing • New P1/2 trial • Oncology • Solid Tumor